Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Vertex Pharmaceuticals (Australia) Pty Ltd,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek),"Cystic fibrosis in people aged 6 years and older with F508del mutation(s) or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CTFR) gene, ineligible for elexacaftor/tezacaftor/ivacaftor and ivacaftor",Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek) (ALYFTREK),Options for investment,Community and Hospital,
